


Product Information



AZD 2858

Item No. 16728

CAS Registry No.: 486424-20-8
Formal Name: 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl-2-pyrazinecarboxamide
MF: C₂₁H₂₃N₇O₃S
FW: 453.5
Purity: ≥98%
Stability: ≥2 years at -20°C
Supplied as: A crystalline solid
UV/Vis.: λ_{max}: 224, 304, 383 nm



Laboratory Procedures

For long term storage, we suggest that AZD 2858 be stored as supplied at -20°C. It should be stable for at least two years.

AZD 2858 is supplied as a crystalline solid. A stock solution may be made by dissolving the AZD 2858 in the solvent of choice. AZD 2858 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of AZD 2858 in these solvents is approximately 5 and 10 mg/ml, respectively.

AZD 2858 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, AZD 2858 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. AZD 2858 has a solubility of approximately 0.1 mg/ml in a 1:5 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Glycogen synthase kinase 3β (GSK3β) was originally identified for its ability to constitutively phosphorylate and inactivate glycogen synthase, preventing glycogen synthesis.¹ It can also phosphorylate proteins that are relevant to osteogenesis and Alzheimer's disease, the latter for which it has earned the moniker, tau phosphorylating kinase.²⁻⁴ AZD 2858 is a pyrazine analog that inhibits GSK3β with a K_i value of 4.9 nM.⁵ It crosses the blood brain barrier and inhibits tau phosphorylation *in vitro* with an IC₅₀ value of 76 nM.⁵ AZD 2858 has also been shown to increase bone mass (*via* Wnt activation) in rats after a two-week treatment with a maximum effective oral dose of 20 mg/kg once daily.⁶ Furthermore, by inhibiting GSK3β, AZD 2858 can stabilize β-catenin in rat mesenchymal stem cells (EC₅₀ = 234 nM), spurring osteoblast differentiation.⁷

References

1. Ring, D.B., Johnson, K.W., Henriksen, E.J., *et al. Diabetes* **52**(3), 588-95 (2003).
2. Asuni, A.A., Hooper, C., Reynolds, C.H., *et al. Eur. J. Neurosci.* **24**(12), 3387-3392 (2006).
3. Phiel, C.J., Wilson, C.A., Lee, V.M., *et al. Nature* **423**(6938), 435-439 (2003).
4. Guerrero, F., Herencia, C., Almadén, Y., *et al. PLoS One* **9**(2), e89179 (2014).
5. Berg, S., Bergh, M., Hellberg, S., *et al. J. Med. Chem.* **55**(21), 9107-9119 (2012).
6. Marsell, R., Sisask, G., Nilsson, Y., *et al. Bone* **50**(3), 619-627 (2012).
7. Gilmour, P.S., O'Shea, P.J., Fagura, M., *et al. Toxicol. Appl. Pharmacol.* **272**(2), 399-407 (2013).

Related Products

For a list of related products please visit: www.caymanchem.com/catalog/16728

WARNING: THIS PRODUCT IS FOR LABORATORY RESEARCH ONLY: NOT FOR ADMINISTRATION TO HUMANS. NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Safety Data Sheet, which has been sent *via* email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Cayman Chemical Company makes **no warranty or guarantee** of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman **warrants only** to the original customer that the material will **meet our specifications at the time of delivery**.

Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have **any obligation or liability**, whether in tort (including negligence) or in contract, for any direct, indirect, incidental or consequential damages, even if Cayman is informed about their possible existence.

This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees.

Buyer's **exclusive remedy** and Cayman's sole liability hereunder shall be limited to a **refund** of the purchase price, or at Cayman's option, the **replacement**, at no cost to Buyer, of all material that does not meet our specifications.

Said refund or replacement is conditioned on Buyer giving written notice to Cayman within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

For further details, please refer to our **Warranty and Limitation of Remedy located on our website and in our catalog**.

Copyright Cayman Chemical Company, 10/21/2014

Cayman Chemical

Mailing address

1180 E. Ellsworth Road
Ann Arbor, MI
48108 USA

Phone

(800) 364-9897
(734) 971-3335

Fax

(734) 971-3640

E-Mail

custserv@caymanchem.com

Web

www.caymanchem.com